New Dengue Vaccine Suspended in Brazil After Severe Adverse Event Reports
Brazil’s Ministry of Health and the National Health Surveillance Agency (ANVISA) suspended a mass vaccination campaign using a new dengue vaccine developed by a Brazilian biomedical research center after severe adverse events, including deaths, were associated with certain batches of the vaccine. Authorities have opened an investigation into the incidents while continuing to assess the […]
Executive Order Directs CDC to Reduce Number of Recommended Childhood Vaccines
On May 29, 2026, President Trump signed an executive order titled “Realigning United States Core Childhood Vaccine Recommendations With Best Practices from Peer, Developed Countries” endorsing a scientific assessment done earlier this year by the U.S. Department of Health and Human Services (DHHS) calling for a reduction in the number of recommended vaccines for children […]
FDA Suspends Chikungunya Vaccine Over Safety Concerns
The U.S. Food and Drug Administration (FDA) announced on Aug. 22, 2025 that it has suspended the license for French drugmaker Valneva’s chikungunya vaccine, warning that its continued use “poses a danger to public health” following a risk–benefit analysis conducted by the agency’s Center for Biologics Evaluation and Research (CBER). The decision came after reports […]
WHO Prequalifies Takeda’s Qdenga Dengue Vaccine
On May 10, 2024, the World Health Organization (WHO) granted prequalification status to the Qdenga (TAK-003) dengue vaccine, developed by Takeda Pharmaceutical Company Ltd. of Tokyo, Japan. The live attenuated virus vaccine is recommended to be given in two doses three months apart to children six to 16 years old living in areas where dengue […]